Archive for April, 2016

Data Transparency in Pharma

Posted on:

Clinical trials are inarguably the most expensive part of drug development, and the most risky to study subjects. Thus, it is only sensible to promote maximal usage of already available data, through data sharing. However, some stakeholders are hesitant to share data, stating concerns for patient confidentiality and vulnerability of intellectual property in pharmaceutical and biotechnology industries. Still, those who have embraced data sharing recognize that it is a public responsibility, as it promotes research progress. The pharmaceutical industry does not always readily share this type of information. However, there is growing pressure that sharing the data will help the…

Read More »